Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX) Following Positive Ph2 Data
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $50.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
